On February 5, 2018, Alexion Pharmaceuticals filed an application for leave to appeal a decision of the Federal Court of Appeal (FCA) dismissing its challenge to the constitutionality of certain of the Patented Medicine Prices Review Board (PMPRB) provisions of the Patent Act: SCC Case No. 37949. The FCA decision, Alexion Pharmaceuticals Inc v Canada (Attorney General), 2017 FCA 241, was previously reported here.